Pulmonary Fibrosis Pipeline 2025: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Pulmonary Fibrosis pipeline constitutes 110+ key companies continuously working towards developing 140+ Pulmonary Fibrosis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Pulmonary Fibrosis Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Pulmonary Fibrosis Market.

The Pulmonary Fibrosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Pulmonary Fibrosis Pipeline Report: https://www.delveinsight.com/sample-request/pulmonary-fibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Pulmonary Fibrosis treatment therapies with a considerable amount of success over the years.
• Pulmonary Fibrosis companies working in the treatment market are Boehringer Ingelheim, PureTech, Guangzhou JOYO Pharma, Tvardi Therapeutics, Pliant Therapeutics, Inc., GlaxoSmithKline, Amgen, Bristol-Myers Squibb, Endeavor Biomedicines, Syndax Pharmaceuticals, Regend Therapeutics, and others, are developing therapies for the Pulmonary Fibrosis treatment
• Emerging Pulmonary Fibrosis therapies in the different phases of clinical trials are- BI 1015550, OFEV (Nintedanib), Pirfenidone, SC1011, TTI-101, PLN-74809, GSK3915393, HZN-825, BMS-986278, taladegib, BI 181947, Axatilimab, REGEND001, and others are expected to have a significant impact on the Pulmonary Fibrosis market in the coming years.
• In November 2025, Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH), a late-stage biotech company focused on developing treatments for unmet needs in CNS, inflammatory, and cardiometabolic disorders, announced that the European Patent Office (EPO) has granted European Patent 3749324. This patent covers the use of brilaroxazine for treating pulmonary fibrosis, including idiopathic pulmonary fibrosis (IPF). The new patent strengthens the drug's global protection portfolio, which already includes the United States, China, and Japan. Additionally, brilaroxazine has been granted Orphan Drug Designation by the U.S. FDA for IPF treatment.
• In September 2025, PureTech Health plc (Nasdaq: PRTC, LSE: PRTC), a biotherapeutics company focused on advancing innovative science into impactful treatments, shared new data from the open-label extension (OLE) of its Phase 2b ELEVATE IPF trial evaluating deupirfenidone (LYT-100) in idiopathic pulmonary fibrosis (IPF). Results revealed that participants who had previously received placebo or pirfenidone for 26 weeks in the randomized phase and then transitioned to deupirfenidone for another 26 weeks in the OLE showed stabilized lung function. Presented as a late-breaking oral session at the 2025 European Respiratory Society (ERS) Congress in Amsterdam, these outcomes underscore deupirfenidone's potential as a future standard of care in IPF treatment.
• In September 2025, United Therapeutics is seeking approval for Tyvaso (treprostinil) in idiopathic pulmonary fibrosis (IPF) following positive results from a Phase III trial. In the TETON-2 study (NCT05255991), the inhaled prostacyclin mimetic significantly improved forced vital capacity (FVC), showing a 95.6 mL increase from baseline. Since FVC is a crucial indicator of breathing restriction in IPF, this outcome is notable. Additionally, the systemic vasodilator delayed the time to the first clinical worsening event, achieving its key secondary endpoint.
• In May 2025, Endeavor BioMedicines, a clinical-stage biotech company developing treatments for serious conditions, presented a post hoc analysis from its completed Phase 2a trial of the investigational drug ENV-101 (taladegib). The findings indicated that patients with idiopathic pulmonary fibrosis (IPF) treated with ENV-101 for 12 weeks showed a marked reduction in pulmonary vessel volume, a significant increase in lung volume, and a trend toward decreased lung fibrosis compared to placebo. This analysis, utilizing Qureight's advanced deep learning CT technology, was highlighted in a poster presentation at the ATS 2025 International Conference.
• In February 2025, Pliant Therapeutics, Inc. (Nasdaq: PLRX) has temporarily halted enrollment and dosing in the ongoing BEACON-IPF Phase 2b trial of bexotegrast for idiopathic pulmonary fibrosis (IPF) following a prespecified data review and recommendations from the independent Data Safety Monitoring Board (DSMB). However, patients already enrolled will continue participation in the trial.
• In January 2025, Mediar Therapeutics entered into a global licensing agreement with Eli Lilly and Company to progress MTX-463 into a Phase II clinical trial for idiopathic pulmonary fibrosis (IPF). MTX-463 is a novel human IgG1 antibody designed to inhibit WISP1-driven fibrotic signaling associated with multiple severe diseases.
• In December 2024, Boston-based clinical-stage biotherapeutics company PureTech announced that its Phase IIb trial of deupirfenidone successfully met all primary and secondary endpoints, demonstrating a reduction in lung function decline in patients with idiopathic pulmonary fibrosis (IPF). The dose-ranging study assessed deupirfenidone (LYT-100) over 26 days, revealing that the high dose effectively slowed lung degeneration. PureTech aims to position the therapy as a new standard of care (SOC) for IPF

Pulmonary Fibrosis Overview
Pulmonary fibrosis is a chronic lung disease in which the lung tissue becomes thickened, stiff, and scarred. This scarring makes it harder for the lungs to work properly, reducing their ability to deliver oxygen into the bloodstream. Over time, people with pulmonary fibrosis may experience symptoms like persistent dry cough, shortness of breath (especially during activity), fatigue, and reduced exercise tolerance. The condition can worsen progressively and may result from various causes, including environmental exposures, autoimmune diseases, infections, certain medications, or it may occur without a known cause (idiopathic pulmonary fibrosis).

Get a Free Sample PDF Report to know more about Pulmonary Fibrosis Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/pulmonary-fibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Pulmonary Fibrosis Drugs Under Different Phases of Clinical Development Include:
• BI 1015550: Boehringer Ingelheim
• OFEV (Nintedanib): Boehringer Ingelheim Pharma GmbH
• Pirfenidone: PureTech
• SC1011: Guangzhou JOYO Pharma
• TTI-101: Tvardi Therapeutics
• PLN-74809: Pliant Therapeutics, Inc.
• GSK3915393: GlaxoSmithKline
• HZN-825: Amgen
• BMS-986278: Bristol-Myers Squibb
• taladegib: Endeavor Biomedicines
• BI 1819479: Boehringer Ingelheim
• Axatilimab: Syndax Pharmaceuticals
• REGEND001: Regend Therapeutics

Pulmonary Fibrosis Route of Administration
Pulmonary Fibrosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Pulmonary Fibrosis Molecule Type Pulmonary Fibrosis Products have been categorized under various Molecule types, such as
• Monoclonal
• Antibody Peptides
• Polymer
• Small molecule
• Gene therapy

Pulmonary Fibrosis Pipeline Therapeutics Assessment
• Pulmonary Fibrosis Assessment by Product Type
• Pulmonary Fibrosis By Stage and Product Type
• Pulmonary Fibrosis Assessment by Route of Administration
• Pulmonary Fibrosis By Stage and Route of Administration
• Pulmonary Fibrosis Assessment by Molecule Type
• Pulmonary Fibrosis by Stage and Molecule Type

DelveInsight's Pulmonary Fibrosis Report covers around 140+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Pulmonary Fibrosis product details are provided in the report. Download the Pulmonary Fibrosis pipeline report to learn more about the emerging Pulmonary Fibrosis therapies
https://www.delveinsight.com/sample-request/pulmonary-fibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Pulmonary Fibrosis Therapeutics Market include:
Key companies developing therapies for Pulmonary Fibrosis are - United Therapeutics, Bellerophon Therapeutics, and MediciNova, and others.

Pulmonary Fibrosis Pipeline Analysis:
The Pulmonary Fibrosis pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Pulmonary Fibrosis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Pulmonary Fibrosis Treatment.
• Pulmonary Fibrosis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Pulmonary Fibrosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Pulmonary Fibrosis market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Pulmonary Fibrosis drugs and therapies
https://www.delveinsight.com/sample-request/pulmonary-fibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Pulmonary Fibrosis Pipeline Market Drivers
• Rising prevalence of IPF worldwide, particularly in aging
• populations, driving demand for new therapies.
• Advancements in diagnostics leading to earlier and more accurate disease detection.
• Strong research and development investments by pharmaceutical companies targeting novel antifibrotic and immunomodulatory mechanisms.
• Regulatory support for orphan drugs, accelerating approvals and incentivizing innovation

Pulmonary Fibrosis Pipeline Market Barriers
• Unclear disease etiology and complex pathophysiology make drug development challenging
• High failure rate in clinical trials due to limited efficacy or safety issues
• Expensive development costs for orphan disease therapies, affecting smaller biotech players
• Limited patient population makes recruitment for large-scale trials difficult
• Side effects of existing antifibrotic drugs hinder patient adherence
• Regulatory challenges in proving long-term efficacy and safety of emerging therapies

Scope of Pulmonary Fibrosis Pipeline Drug Insight
• Coverage: Global
• Key Pulmonary Fibrosis Companies: Boehringer Ingelheim, PureTech, Guangzhou JOYO Pharma, Tvardi Therapeutics, Pliant Therapeutics, Inc., GlaxoSmithKline, Amgen, Bristol-Myers Squibb, Endeavor Biomedicines, Syndax Pharmaceuticals, Regend Therapeutics, and others
• Key Pulmonary Fibrosis Therapies: BI 1015550, OFEV (Nintedanib), Pirfenidone, SC1011, TTI-101, PLN-74809, GSK3915393, HZN-825, BMS-986278, taladegib, BI 181947, Axatilimab, REGEND001, and others
• Pulmonary Fibrosis Therapeutic Assessment: Pulmonary Fibrosis current marketed and Pulmonary Fibrosis emerging therapies
• Pulmonary Fibrosis Market Dynamics: Pulmonary Fibrosis market drivers and Pulmonary Fibrosis market barriers

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on
life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.